



## **Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference**

February 25, 2021

PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate virtually in the 41<sup>st</sup> Annual Cowen Healthcare Conference on Tuesday, March 2, 2021, at 11:10 a.m. ET, and host investor meetings.

To access the live webcast, please visit the "Investors and News" section of the Oyster Point Pharma website at <https://investors.oysterpointrx.com/>.

### **About Oyster Point Pharma, Inc.**

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit. OC-01 (varenicline) nasal spray is an investigational new drug and has not been approved for any use in any country. The safety and efficacy of OC-01 (varenicline) nasal spray have not previously been established.

#### **Investor Contact:**

Tim McCarthy  
LifeSci Advisors, LLC  
(212) 915-2564  
[investors@oysterpointrx.com](mailto:investors@oysterpointrx.com)

#### **Media Contact:**

Sheryl Seapy  
W2O Group  
(213) 262-9390  
[sseapy@w2ogroup.com](mailto:sseapy@w2ogroup.com)